ClinicalTrials.gg
CompletedNCT04503551PAVILIONUpdated Apr 2, 2026Results posted

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

A Phase 3 interventional study of PDS Implant Pre-Filled with 100 mg/mL Ranibizumab and Intravitreal Ranibizumab 0.5 mg Injection in Diabetic Retinopathy, sponsored by Hoffmann-La Roche. Completed at 65 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing ranibizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Ranibizumab · Diabetic Retinopathy.

Enrollment
5th of 34
174 · median 57
Started
2020
with 1 other
Phase 3
9 of 34
1 open now
Registered
28th of 34
by date
Lead sponsor
1 of 34
Hoffmann-La Roche

Among the 34 studies testing ranibizumab in Diabetic Retinopathy, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 9 in phase 3, and was the 28th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 34 studies testing ranibizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing ranibizumab in Diabetic Retinopathy, or all of them as a file.
02

Study summary

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator Arm

03

Conditions studied

  • Diabetic Retinopathy

Keywords

  • Port Delivery System; ranibizumab; Diabetic Retinopathy; anti-VEGF, nonproliferative diabetic retinopathy, retina, vision loss, retinal disease, eye disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age ≥18 years at time of signing Form
  • Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
  • level of ≤12% within 2 months prior to screening or at screening

Inclusion Criteria for Study Eye

  • Moderately severe or severe NPDR (ETDRS-DRSS level 47 or 53)
  • BCVA score of ≥ 69 letters (20/40 approximate Snellen equivalent or better)

Exclusion Criteria:

  • Uncontrolled blood pressure
  • Cerebrovascular accident or myocardial infarction within 6 months prior to randomization
  • Atrial fibrillation diagnosis or worsening within 6 months prior to randomization
  • Current systemic treatment for a confirmed active systemic infection
  • Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis, or anticipated to require hemodialysis or peritoneal dialysis at any time during the study
  • History of other disease, other non-diabetic metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of ranibizumab or surgical placement of the PDS implant; that might affect interpretation of the results of the study; or that renders the patient at high risk for treatment complications in the opinion of the investigator or Sponsor

Ocular Exclusion Criteria for Study Eye:

  • Presence of center-involved diabetic macular edema (defined as CST ≥325 µm)
  • Any intravitreal anti-VEGF treatment at any time prior to randomization
  • Any use of medicated intraocular implants, including Ozurdex® or Iluvien® implants at any time prior to randomization
  • Any intravitreal treatment at any time prior to randomization
  • Any periocular (e.g., subtenon) corticosteroid treatment at any time prior to randomization
  • Any PRP at any time prior to randomization
  • Any macular laser photocoagulation (such as micropulse and focal or grid laser) at any time prior to randomization
  • Active intraocular inflammation (grade trace or above)
  • abnormalities of the vitreous-retinal interface involving the macular area or disrupting the macular architecture, such as vitreous-retinal traction or epiretinal membrane (assessed by the investigator and confirmed by the central reading center)
  • Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a participant's participation in the study
  • History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
  • Any concurrent ocular condition (e.g., cataract, epiretinal membrane) that would require surgical intervention during the study to prevent or treat visual loss that might result from that condition
  • Any concurrent ocular condition (e.g., amblyopia, strabismus) that may affect interpretation of study results
  • History of other ocular diseases that gives reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab, that might affect interpretation of study results, or that renders the participant at high risk for treatment complications

Ocular Exclusion Criteria for Either Eye

  • Suspected or active ocular or periocular infection of either eye
  • Any history uveitis including idiopathic, drug-associated or -associated uveitis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
174 participants (actual)

Study arms

  • Experimental
    PDS Arm

    Participants randomized to the PDS arm will receive two intravitreal ranibizumab injections and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 36-weeks (Q36W) thereafter

    Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab · Drug: Intravitreal Ranibizumab 0.5 mg Injection

  • Other
    Comparator Arm

    Participants randomized to the comparator arm will undergo study visits every 4 weeks (Q4W) for comprehensive clinical monitoring until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q36W thereafter. Participants will be eligible to receive intravitreal ranibizumab 0.5 mg injections if treatment eligibility criteria are met.

    Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab · Drug: Intravitreal Ranibizumab 0.5 mg Injection

Interventions

  • DrugPDS Implant Pre-Filled with 100 mg/mL Ranibizumab

    Will be administered as per the schedule described in individual arm.

  • Will be administered as per the schedule described in individual arm.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at Week 52

    ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy. The Cochran-Mantel Haenszel (CMH) method was used for analysis and weighted percentage of participants are estimated and reported in this outcome measure. Participants receiving supplemental treatments, prohibited therapy, or panretinal photocoagulation (PRP) were considered non-responders. Missing values not preceded by these intercurrent events were imputed using the last observation carried forward method. SD OCT= spectral-domain optical coherence tomography.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Rate of Participants Developing a Vision-Threatening Complication or Center-involved Diabetic Macular Edema (CI-DME) Through Week 52

    A vision threatening complication is defined as proliferative DR (PDR) or anterior segment neovascularization (ASNV) or center-involved diabetic macular edema (CI-DME). CI-DME is defined as central foveal thickness (CST) ≥325 micrometres (μm) on spectral-domain optical coherence tomography (SD-OCT). Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye. The rate of participants was calculated using the Kaplan-Meier (KM) method.

    Time frame: From Baseline through Week 52

  2. Rate of Participants Developing PDR or ASNV Through Week 52

    The KM method was used for analysis, and estimates are in terms of event rate. Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye.

    Time frame: From Baseline through Week 52

  3. Rate of Participants Developing CI-DME Through Week 52

    CI-DME is defined as CST ≥325 μm on SD-OCT. The KM method was used for analysis, and estimated in terms of event rate. Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye.

    Time frame: From Baseline through Week 52

  4. Rate of Participants Developing a ≥ 2-Step Worsening From Baseline on the ETDRS-DRSS Through Week 52

    ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR ), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy. Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye. The rate of participants developing ≥ 2-step worsening on the ETDRS-DRSS was calculated using the KM method.

    Time frame: From Baseline through Week 52

  5. Percentage of Participants With a ≥ 3-Step Improvement From Baseline on the ETDRS-DRSS at Week 52

    ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR ), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy. Participants receiving supplemental treatments, prohibited therapy, or panretinal photocoagulation (PRP) were considered non-responders. Missing values not preceded by these intercurrent events were imputed using the last observation carried forward method. Percentages are rounded off to the nearest decimal point.

    Time frame: Week 52

  6. Rate of Participants Developing a ≥ 3-Step Worsening From Baseline on the ETDRS-DRSS Through Week 52

    ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR ), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy. Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye. The rate of participants developing ≥ 3-step worsening on the ETDRS-DRSS was calculated using the KM method.

    Time frame: From Baseline through Week 52

  7. Percentage of Participants With a ≥ 2-Step Improvement From Baseline on the ETDRS-DRSS Over Time

    ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale , from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy.

    Time frame: Baseline up to Week 112

  8. Percentage of Participants With a ≥ 3-step Improvement From Baseline on the ETDRS-DRSS Over Time

    ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR ), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale , from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy.

    Time frame: Baseline up to Week 112

  9. Time to First Development of Either PDR, ASNV, or CI-DME

    Time frame: Baseline up to Week 112

  10. Time to First Development of PDR or ASNV

    Time frame: Baseline up to Week 112

  11. Time to First Development of CI-DME

    CI-DME is defined as CST ≥325 μm on SD-OCT.

    Time frame: Baseline up to Week 112

  12. Time to First Development of a ≥ 2-Step Worsening From Baseline on the ETDRS-DRSS

    ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy.

    Time frame: Baseline up to Week 112

  13. Time to First Development of a ≥ 3-Step Worsening From Baseline on the ETDRS-DRSS

    ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy.

    Time frame: Baseline up to Week 112

  14. Change From Baseline in Best-Corrected Visual Acuity (BCVA) as Measured on the ETDRS Chart Over Time

    BCVA was measured at a starting test distance of 4 meters using a set of three Precision Vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R). The BCVA letter score ranges from 0 to 100 (best score attainable), and a higher score indicates better visual acuity.

    Time frame: Baseline up to Week 112

  15. Percentage of Participants Who Lost <15, <10 and <5 Letters in BCVA From Baseline Over Time

    BCVA was measured at a starting test distance of 4 meters using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R). The BCVA letter score ranges from 0 to 100 (best score attainable), and a higher score indicates better visual acuity.

    Time frame: Baseline up to Week 112

  16. Percentage of Participants With a BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better Over Time

    BCVA is measured using the ETDRS visual acuity chart starting at a test distance of 4 meters. The number of letters read correctly, Snellen fraction are converted to a decimal scale. There are 11 lines on a standard Snellen chart ranging from 0.1 (20/200) at worst to 2.0 (20/10) at best. 20/20 on the decimal scale is equal to 1.0. The higher the number of letters read correctly (higher number on the decimal scale), the better the vision (or visual acuity). The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the ETDRS chart.

    Time frame: Baseline up to Week 112

  17. Change From Baseline in CST as Measured on SD-OCT Over Time

    CST is defined as the average thickness of the central 1 millimeter (mm) circle of the ETDRS grid centered on the fovea measured between the internal limiting membrane and the Bruch's membrane. CST is measured using spectral domain optical coherence tomography (SD-OCT). A central reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.

    Time frame: Baseline up to Week 112

  18. Change From Baseline in Total Macular Volume (TMV) as Measured on SD-OCT Over Time

    Total macular volume in cubic millimeter (mm\^3), is the calculated volume from the layers of the retina based off OCT imaging. TMV is measured using SD-OCT.

    Time frame: Baseline up to Week 112

  19. Number of Participants With Ocular Adverse Events (AEs) and Severity of Ocular AEs in the PDS Arm

    An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product,regardless of causal attribution.An adverse event can therefore be any unfavourable \& unintended sign,symptom,or disease temporally associated with the use of a pharmaceutical product,whether considered related to the pharmaceutical product.Preexisting conditions which worsen during a study are also considered as adverse events.Ocular AEs are the events which are localized in the ocular region,graded according to the AE Severity Grading Scale as Mild:discomfort noticed,but no disruption of normal daily activity;Moderate:Discomfort sufficient to reduce or affect normal daily activity;Severe incapacitating with inability to work or to perform normal daily activity.Number of participants with ocular AEs in the study eye are reported in this outcome measure.As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only.

    Time frame: From first dose of study drug through Week 52

  20. Number of Participants With Non-ocular AEs in the PDS Arm

    An adverse event is any untoward medical occurrence in a clinical investigation participant subject administered a pharmaceutical product, regardless of causal attribution. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only.

    Time frame: From first dose of study drug through Week 52

  21. Number of Participants With At Least One Ocular Adverse Events of Special Interest (AESI) in the PDS Arm

    An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Ocular AESI include vitreous hemorrhage; endophthalmitis; retinal detachment; conjunctival retraction; conjunctival erosion; conjunctival bleb or conjunctival filtering bleb leak; hyphema; cataract; device dislocation. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only.

    Time frame: From first dose of study drug through Week 52

  22. Number of Participants With At Least One Ocular AESI During the Postoperative Period in the PDS Arm

    An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Ocular AESI include vitreous hemorrhage; endophthalmitis; retinal detachment; conjunctival retraction; conjunctival erosion; conjunctival bleb or conjunctival filtering bleb leak; hyphema; cataract; device dislocation. The ocular AESIs in the study eye were categorized based on onset as, Postoperative Period: onset within 37 days post initial implantation. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only.

    Time frame: From Day 1 to Day 37 Postoperative Period

  23. Serum Concentration of Ranibizumab Observed Over Time

    Time frame: Baseline up to week 112

  24. Pharmacokinetic (PK) Parameter Value Area Under the Concentration

    Time frame: At Baseline and multiple time points up to week 112

  25. Minimum Serum Concentration (Cmin) of Ranibizumab Observed Over Time

    Time frame: Baseline up to week 112

  26. Half-Life (t ½) of Ranibizumab Observed Over Time

    Time frame: Baseline up to Week 112

  27. Number of Participants With Anti-Drug Antibodies (ADAs) to Ranibizumab

    The numbers of ADA-positive participants at baseline and after drug administration were to be summarized for participants exposed to Ranibizumab. PDS patients who were ADA positive at the reference visit and ADA titer increased after implant; in this case, the titer of one or more samples collected after implant must be at least 4-fold greater than the titer of the reference visit sample. These patients are considered to have treatment-enhanced ADA responses.

    Time frame: Baseline up to Week 112

  28. Number of Participants With Neutralizing Antibodies to Ranibizumab

    The numbers of neutralizing antibodies positive participants at baseline and after drug administration were to be summarized for participants exposed to Ranibizumab.

    Time frame: Baseline up to Week 112

  29. Percentage of Participants Who do Not Undergo Supplemental Treatment With Intravitreal Ranibizumab Within Each Refill-Exchange Interval

    Time frame: Baseline up to Week 112

  30. Percentage of Participants With At Least One AE Related to Study Device or Procedure in the PDS Arm

    An AE related to study device or procedure is defined as any adverse event related to the use of an investigational medical device. This includes any adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, operation, or any malfunction of the investigational medical device and any adverse event resulting from use error or from intentional misuse of the investigational medical device. PDS Device refers to the implant, insertion tool, initial fill needle, refill needle, and explant tool. PDS Procedure refers to the initial fill, implant insertion, refill-exchange, and explantation. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only. Percentages are rounded off to the nearest decimal point.

    Time frame: From first dose of study drug through Week 52

  31. Percentage of Participants With Serious Adverse Effects Related to Study Device or Procedure in the PDS Arm

    An AE related to study device or procedure is defined as any AE related to the use of an investigational medical device \& includes any AE resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, operation, or any malfunction of the investigational medical device \& any AE resulting from use error or from intentional misuse of the investigational medical device. PDS refers to the implant, insertion tool, initial fill needle, refill needle \& explant tool. PDS procedure refers to the initial fill, implant insertion, refill-exchange, \& explantation. Any AE related to study device or procedure that resulted in any of a serious AE such as death, life-threatening illness or injury or permanent impairment of a body structure or a body function was considered serious. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only. Percentages are rounded off to the nearest decimal point.

    Time frame: From Day 1 up to Week 52

  32. Percentage of Participants With Absence of Intraretinal Fluid, Subretinal Fluid or Both Over Time

    Absence of intraretinal fluid and subretinal fluid are measured in the central 1 mm subfield on SD-OCT. Percentages are rounded off to the nearest decimal point.

    Time frame: Baseline up to Week 112

  33. Percentage of Participants Who Report Preferring PDS Treatment to Intravitreal Ranibizumab Treatment, as Measured by the PDS Patient Preference Questionnaire (PPPQ) at Week 52

    The PPPQ is a 3-item questionnaire that captures a participant's preference for treatment (PDS or intravitreal injections), the strength of their preference (very strong, fairly strong, and not very strong) and the reasons for their preference (less worry or nervousness, requires less time for treatment, less discomfort, fewer treatments and other reason). As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only. Percentages are rounded off to the nearest decimal point.

    Time frame: Week 52

  34. Number of Participants With Device Deficiencies

    A device deficiency is defined as any inadequacy with respect to labeling, identity, quality, durability, reliability, usability, safety, or performance of an investigational device, including malfunctions, use errors, or inadequacy in information supplied by the manufacturer. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only and device deficiencies were to be recorded in the electronic capture system (EDC) after implementation of protocol Version 2 (i.e., for participants implanted after 14 June 2021).

    Time frame: Baseline up to Week 52

07

Results

Posted Nov 25, 2025

Participant flow

Participants were enrolled in this study at 50 investigative sites in the United States from 10 August 2020. The study is ongoing. The analyses presented in this results summary are based on a primary completion date (clinical cut-off) of 03 October 2022.

Participant flow — Overall Study
MilestonePDS With Ranibizumab 100 mg/mLComparator Arm
Started10668
Safety evaluable population10568
Completed00
Not completed10668
Withdrew: Withdrawal by subject53
Withdrew: Physician decision10
Withdrew: Death01
Withdrew: Lost to follow-up12
Withdrew: Ongoing at week 529962

Outcome measures

PrimaryPercentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at Week 52

ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy. The Cochran-Mantel Haenszel (CMH) method was used for analysis and weighted percentage of participants are estimated and reported in this outcome measure. Participants receiving supplemental treatments, prohibited therapy, or panretinal photocoagulation (PRP) were considered non-responders. Missing values not preceded by these intercurrent events were imputed using the last observation carried forward method. SD OCT= spectral-domain optical coherence tomography.

Time frame:
Baseline, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at Week 52
percentage of participantsPDS With Ranibizumab 100 mg/mLComparator Arm
Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at Week 5280.19.0
Statistical analysis
  • PDS With Ranibizumab 100 mg/mL vs Comparator Arm · Cochran-Mantel-Haenszel · p = <0.0001 · Cmh weighted percentage difference: 71.1 · 95.04% CI 61.0 to 81.2Stratification was done by baseline ETDRS-DRSS level (47 vs.53) \& baseline intraretinal/subretinal fluid status on SD-OCT (present vs. absent).
SecondaryRate of Participants Developing a Vision-Threatening Complication or Center-involved Diabetic Macular Edema (CI-DME) Through Week 52

A vision threatening complication is defined as proliferative DR (PDR) or anterior segment neovascularization (ASNV) or center-involved diabetic macular edema (CI-DME). CI-DME is defined as central foveal thickness (CST) ≥325 micrometres (μm) on spectral-domain optical coherence tomography (SD-OCT). Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye. The rate of participants was calculated using the Kaplan-Meier (KM) method.

Time frame:
From Baseline through Week 52
Reported as:
Number · percentage of participants
Rate of Participants Developing a Vision-Threatening Complication or Center-involved Diabetic Macular Edema (CI-DME) Through Week 52
percentage of participantsPDS With Ranibizumab 100 mg/mLComparator Arm
Rate of Participants Developing a Vision-Threatening Complication or Center-involved Diabetic Macular Edema (CI-DME) Through Week 527.147.0
Statistical analysis
  • PDS With Ranibizumab 100 mg/mL vs Comparator Arm · Stratified Log-Rank · p = < 0.0001 · Stratified hazard ratio: 0.1 · 95.04% CI 0.1 to 0.3
SecondaryRate of Participants Developing PDR or ASNV Through Week 52

The KM method was used for analysis, and estimates are in terms of event rate. Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye.

Time frame:
From Baseline through Week 52
Reported as:
Number · percentage of participants
Rate of Participants Developing PDR or ASNV Through Week 52
percentage of participantsPDS With Ranibizumab 100 mg/mLComparator Arm
Rate of Participants Developing PDR or ASNV Through Week 521.042.4
Statistical analysis
  • PDS With Ranibizumab 100 mg/mL vs Comparator Arm · Stratified Log-Rank · p = < 0.0001 · Stratified hazard ratio: 0.1 · 95.04% CI 0.1 to 0.1
SecondaryRate of Participants Developing CI-DME Through Week 52

CI-DME is defined as CST ≥325 μm on SD-OCT. The KM method was used for analysis, and estimated in terms of event rate. Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye.

Time frame:
From Baseline through Week 52
Reported as:
Number · percentage of participants
Rate of Participants Developing CI-DME Through Week 52
percentage of participantsPDS With Ranibizumab 100 mg/mLComparator Arm
Rate of Participants Developing CI-DME Through Week 527.147.0
Statistical analysis
  • PDS With Ranibizumab 100 mg/mL vs Comparator Arm · Stratified Log-Rank · p = <0.0001 · Stratified hazard ratio: 0.1 · 95.04% CI 0.1 to 0.3
SecondaryRate of Participants Developing a ≥ 2-Step Worsening From Baseline on the ETDRS-DRSS Through Week 52

ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR ), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy. Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye. The rate of participants developing ≥ 2-step worsening on the ETDRS-DRSS was calculated using the KM method.

Time frame:
From Baseline through Week 52
Reported as:
Number · percentage of participants
Rate of Participants Developing a ≥ 2-Step Worsening From Baseline on the ETDRS-DRSS Through Week 52
percentage of participantsPDS With Ranibizumab 100 mg/mLComparator Arm
Rate of Participants Developing a ≥ 2-Step Worsening From Baseline on the ETDRS-DRSS Through Week 523.046.4
Statistical analysis
  • PDS With Ranibizumab 100 mg/mL vs Comparator Arm · Stratified Log-Rank · p = <0.0001 · Stratified hazard ratio: 0.1 · 95.04% CI 0.1 to 0.2
SecondaryPercentage of Participants With a ≥ 3-Step Improvement From Baseline on the ETDRS-DRSS at Week 52

ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR ), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy. Participants receiving supplemental treatments, prohibited therapy, or panretinal photocoagulation (PRP) were considered non-responders. Missing values not preceded by these intercurrent events were imputed using the last observation carried forward method. Percentages are rounded off to the nearest decimal point.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 3-Step Improvement From Baseline on the ETDRS-DRSS at Week 52
percentage of participantsPDS With Ranibizumab 100 mg/mLComparator Arm
Percentage of Participants With a ≥ 3-Step Improvement From Baseline on the ETDRS-DRSS at Week 5215.10
Statistical analysis
  • PDS With Ranibizumab 100 mg/mL vs Comparator Arm · Fisher Exact · p = 0.0003 · Percentage difference: 15.1 · 95.04% CI 8.3 to 21.9
SecondaryRate of Participants Developing a ≥ 3-Step Worsening From Baseline on the ETDRS-DRSS Through Week 52

ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR ), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy. Composite strategy (i.e., considered to be an event) was applied to participants who received supplemental or prohibited therapy or PRP in the study eye. The rate of participants developing ≥ 3-step worsening on the ETDRS-DRSS was calculated using the KM method.

Time frame:
From Baseline through Week 52
Reported as:
Number · percentage of participants
Rate of Participants Developing a ≥ 3-Step Worsening From Baseline on the ETDRS-DRSS Through Week 52
percentage of participantsPDS With Ranibizumab 100 mg/mLComparator Arm
Rate of Participants Developing a ≥ 3-Step Worsening From Baseline on the ETDRS-DRSS Through Week 523.045.1
Statistical analysis
  • PDS With Ranibizumab 100 mg/mL vs Comparator Arm · Stratified Log-Rank · p = <0.0001 · Stratified hazard ratio: 0.1 · 95.04% CI 0.1 to 0.2
SecondaryPercentage of Participants With a ≥ 2-Step Improvement From Baseline on the ETDRS-DRSS Over Time

ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale , from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants With a ≥ 3-step Improvement From Baseline on the ETDRS-DRSS Over Time

ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR ), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale , from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryTime to First Development of Either PDR, ASNV, or CI-DME
Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryTime to First Development of PDR or ASNV
Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryTime to First Development of CI-DME

CI-DME is defined as CST ≥325 μm on SD-OCT.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryTime to First Development of a ≥ 2-Step Worsening From Baseline on the ETDRS-DRSS

ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryTime to First Development of a ≥ 3-Step Worsening From Baseline on the ETDRS-DRSS

ETDRS-DRSS classifies diabetic retinopathy (DR) into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). DRSS grades= 10 (DR absent) - 85 (very advanced PDR), DRSS 90 = ungradable. All DRSS values are converted into a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR), allowing derivation of ≥2-step change from baseline for post-baseline assessment. A lower score represents less advanced diabetic retinopathy.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryChange From Baseline in Best-Corrected Visual Acuity (BCVA) as Measured on the ETDRS Chart Over Time

BCVA was measured at a starting test distance of 4 meters using a set of three Precision Vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R). The BCVA letter score ranges from 0 to 100 (best score attainable), and a higher score indicates better visual acuity.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Lost <15, <10 and <5 Letters in BCVA From Baseline Over Time

BCVA was measured at a starting test distance of 4 meters using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R). The BCVA letter score ranges from 0 to 100 (best score attainable), and a higher score indicates better visual acuity.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants With a BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better Over Time

BCVA is measured using the ETDRS visual acuity chart starting at a test distance of 4 meters. The number of letters read correctly, Snellen fraction are converted to a decimal scale. There are 11 lines on a standard Snellen chart ranging from 0.1 (20/200) at worst to 2.0 (20/10) at best. 20/20 on the decimal scale is equal to 1.0. The higher the number of letters read correctly (higher number on the decimal scale), the better the vision (or visual acuity). The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the ETDRS chart.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryChange From Baseline in CST as Measured on SD-OCT Over Time

CST is defined as the average thickness of the central 1 millimeter (mm) circle of the ETDRS grid centered on the fovea measured between the internal limiting membrane and the Bruch's membrane. CST is measured using spectral domain optical coherence tomography (SD-OCT). A central reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryChange From Baseline in Total Macular Volume (TMV) as Measured on SD-OCT Over Time

Total macular volume in cubic millimeter (mm\^3), is the calculated volume from the layers of the retina based off OCT imaging. TMV is measured using SD-OCT.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryNumber of Participants With Ocular Adverse Events (AEs) and Severity of Ocular AEs in the PDS Arm

An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product,regardless of causal attribution.An adverse event can therefore be any unfavourable \& unintended sign,symptom,or disease temporally associated with the use of a pharmaceutical product,whether considered related to the pharmaceutical product.Preexisting conditions which worsen during a study are also considered as adverse events.Ocular AEs are the events which are localized in the ocular region,graded according to the AE Severity Grading Scale as Mild:discomfort noticed,but no disruption of normal daily activity;Moderate:Discomfort sufficient to reduce or affect normal daily activity;Severe incapacitating with inability to work or to perform normal daily activity.Number of participants with ocular AEs in the study eye are reported in this outcome measure.As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only.

Time frame:
From first dose of study drug through Week 52
Reported as:
Count of participants · Participants
Number of Participants With Ocular Adverse Events (AEs) and Severity of Ocular AEs in the PDS Arm
ParticipantsPDS With Ranibizumab 100 mg/mL
Ocular AEs84
Ocular AEs: Mild55
Ocular AEs: Moderate21
Ocular AEs: Severe8
SecondaryNumber of Participants With Non-ocular AEs in the PDS Arm

An adverse event is any untoward medical occurrence in a clinical investigation participant subject administered a pharmaceutical product, regardless of causal attribution. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only.

Time frame:
From first dose of study drug through Week 52
Reported as:
Count of participants · Participants
Number of Participants With Non-ocular AEs in the PDS Arm
ParticipantsPDS With Ranibizumab 100 mg/mL
Number of Participants With Non-ocular AEs in the PDS Arm59
SecondaryNumber of Participants With At Least One Ocular Adverse Events of Special Interest (AESI) in the PDS Arm

An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Ocular AESI include vitreous hemorrhage; endophthalmitis; retinal detachment; conjunctival retraction; conjunctival erosion; conjunctival bleb or conjunctival filtering bleb leak; hyphema; cataract; device dislocation. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only.

Time frame:
From first dose of study drug through Week 52
Reported as:
Count of participants · Participants
Number of Participants With At Least One Ocular Adverse Events of Special Interest (AESI) in the PDS Arm
ParticipantsPDS With Ranibizumab 100 mg/mL
Number of Participants With At Least One Ocular Adverse Events of Special Interest (AESI) in the PDS Arm17
SecondaryNumber of Participants With At Least One Ocular AESI During the Postoperative Period in the PDS Arm

An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Ocular AESI include vitreous hemorrhage; endophthalmitis; retinal detachment; conjunctival retraction; conjunctival erosion; conjunctival bleb or conjunctival filtering bleb leak; hyphema; cataract; device dislocation. The ocular AESIs in the study eye were categorized based on onset as, Postoperative Period: onset within 37 days post initial implantation. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only.

Time frame:
From Day 1 to Day 37 Postoperative Period
Reported as:
Count of participants · Participants
Number of Participants With At Least One Ocular AESI During the Postoperative Period in the PDS Arm
ParticipantsPDS With Ranibizumab 100 mg/mL
Postoperative Period10
Follow-up Period9
SecondarySerum Concentration of Ranibizumab Observed Over Time
Time frame:
Baseline up to week 112

Results for this outcome have not been posted.

SecondaryPharmacokinetic (PK) Parameter Value Area Under the Concentration
Time frame:
At Baseline and multiple time points up to week 112

Results for this outcome have not been posted.

SecondaryMinimum Serum Concentration (Cmin) of Ranibizumab Observed Over Time
Time frame:
Baseline up to week 112

Results for this outcome have not been posted.

SecondaryHalf-Life (t ½) of Ranibizumab Observed Over Time
Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) to Ranibizumab

The numbers of ADA-positive participants at baseline and after drug administration were to be summarized for participants exposed to Ranibizumab. PDS patients who were ADA positive at the reference visit and ADA titer increased after implant; in this case, the titer of one or more samples collected after implant must be at least 4-fold greater than the titer of the reference visit sample. These patients are considered to have treatment-enhanced ADA responses.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryNumber of Participants With Neutralizing Antibodies to Ranibizumab

The numbers of neutralizing antibodies positive participants at baseline and after drug administration were to be summarized for participants exposed to Ranibizumab.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who do Not Undergo Supplemental Treatment With Intravitreal Ranibizumab Within Each Refill-Exchange Interval
Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants With At Least One AE Related to Study Device or Procedure in the PDS Arm

An AE related to study device or procedure is defined as any adverse event related to the use of an investigational medical device. This includes any adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, operation, or any malfunction of the investigational medical device and any adverse event resulting from use error or from intentional misuse of the investigational medical device. PDS Device refers to the implant, insertion tool, initial fill needle, refill needle, and explant tool. PDS Procedure refers to the initial fill, implant insertion, refill-exchange, and explantation. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only. Percentages are rounded off to the nearest decimal point.

Time frame:
From first dose of study drug through Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One AE Related to Study Device or Procedure in the PDS Arm
percentage of participantsPDS With Ranibizumab 100 mg/mL
Percentage of Participants With At Least One AE Related to Study Device or Procedure in the PDS Arm70.5
SecondaryPercentage of Participants With Serious Adverse Effects Related to Study Device or Procedure in the PDS Arm

An AE related to study device or procedure is defined as any AE related to the use of an investigational medical device \& includes any AE resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, operation, or any malfunction of the investigational medical device \& any AE resulting from use error or from intentional misuse of the investigational medical device. PDS refers to the implant, insertion tool, initial fill needle, refill needle \& explant tool. PDS procedure refers to the initial fill, implant insertion, refill-exchange, \& explantation. Any AE related to study device or procedure that resulted in any of a serious AE such as death, life-threatening illness or injury or permanent impairment of a body structure or a body function was considered serious. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only. Percentages are rounded off to the nearest decimal point.

Time frame:
From Day 1 up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Effects Related to Study Device or Procedure in the PDS Arm
percentage of participantsPDS With Ranibizumab 100 mg/mL
Percentage of Participants With Serious Adverse Effects Related to Study Device or Procedure in the PDS Arm1.0
SecondaryPercentage of Participants With Absence of Intraretinal Fluid, Subretinal Fluid or Both Over Time

Absence of intraretinal fluid and subretinal fluid are measured in the central 1 mm subfield on SD-OCT. Percentages are rounded off to the nearest decimal point.

Time frame:
Baseline up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Report Preferring PDS Treatment to Intravitreal Ranibizumab Treatment, as Measured by the PDS Patient Preference Questionnaire (PPPQ) at Week 52

The PPPQ is a 3-item questionnaire that captures a participant's preference for treatment (PDS or intravitreal injections), the strength of their preference (very strong, fairly strong, and not very strong) and the reasons for their preference (less worry or nervousness, requires less time for treatment, less discomfort, fewer treatments and other reason). As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only. Percentages are rounded off to the nearest decimal point.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Report Preferring PDS Treatment to Intravitreal Ranibizumab Treatment, as Measured by the PDS Patient Preference Questionnaire (PPPQ) at Week 52
percentage of participantsPDS With Ranibizumab 100 mg/mL
Percentage of Participants Who Report Preferring PDS Treatment to Intravitreal Ranibizumab Treatment, as Measured by the PDS Patient Preference Questionnaire (PPPQ) at Week 5276.6
SecondaryNumber of Participants With Device Deficiencies

A device deficiency is defined as any inadequacy with respect to labeling, identity, quality, durability, reliability, usability, safety, or performance of an investigational device, including malfunctions, use errors, or inadequacy in information supplied by the manufacturer. As prespecified in the protocol, this outcome measure was applicable to participants in the PDS arm only and device deficiencies were to be recorded in the electronic capture system (EDC) after implementation of protocol Version 2 (i.e., for participants implanted after 14 June 2021).

Time frame:
Baseline up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Device Deficiencies
ParticipantsPDS With Ranibizumab 100 mg/mL
Number of Participants With Device Deficiencies9

Adverse events

Collected over From study start through primary completion date (up to Week 52). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PDS With Ranibizumab 100 mg/mL0/106 (0%)17/105 (16.2%)89/105 (84.8%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPDS With Ranibizumab 100 mg/mL
Cardiac failure congestiveCardiac disorders3/105
Angina unstableCardiac disorders1/105
Atrial fibrillationCardiac disorders1/105
Coronary artery diseaseCardiac disorders1/105
CataractEye disorders1/105
Diabetic retinopathyEye disorders1/105
Ocular hypertensionEye disorders1/105
Retinal artery occlusionEye disorders1/105
Retinal detachmentEye disorders1/105
Vitreous haemorrhageEye disorders1/105
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPDS With Ranibizumab 100 mg/mL
Conjunctival haemorrhageEye disorders79/105
COVID-19Infections and infestations16/105
Vitreous haemorrhageEye disorders14/105
Conjunctival hyperaemiaEye disorders12/105
Conjunctival oedemaEye disorders10/105
IritisEye disorders10/105
Punctate keratitisEye disorders10/105
Eye painEye disorders9/105
Foreign body sensation in eyesEye disorders9/105
Vitreous detachmentEye disorders9/105

Baseline characteristics

Intent to treat (ITT) Population included all participants who were randomized. Participants were grouped according to treatment assigned at randomization.

Age, Continuous
Age, Continuous(years)PDS With Ranibizumab 100 mg/mLComparator ArmTotal
Mean53.7 ± 11.3254.1 ± 12.3053.9 ± 11.68
Sex: Female, Male
Sex: Female, Male(Participants)PDS With Ranibizumab 100 mg/mLComparator ArmTotal
Female472774
Male5941100
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PDS With Ranibizumab 100 mg/mLComparator ArmTotal
Hispanic or Latino432972
Not Hispanic or Latino6339102
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PDS With Ranibizumab 100 mg/mLComparator ArmTotal
American Indian or Alaska Native404
Asian9817
Native Hawaiian or Other Pacific Islander202
Black or African American14418
White7352125
More than one race000
Unknown or Not Reported448
08

Study locations

65 sites
  • Barnet Dulaney Perkins Eye Center
    Mesa, Arizona 85206, United States
  • Retinal Consultants of Arizona;Opthalmology
    Phoenix, Arizona 85014, United States
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • California Retina Consultants
    Bakersfield, California 93309, United States
  • The Retina Partners
    Encino, California 91436, United States
  • Retina Consultants of Orange County;Clinical Research
    Fullerton, California 92835, United States
  • Jules Stein Eye Institute/ UCLA
    Los Angeles, California 90095, United States
  • California Eye Specialists Medical Group
    Pasadena, California 91107, United States
  • Kaiser Permanente;RESEARCH AND EVALUATION
    Riverside, California 92505, United States
  • Retina Consultants Medical Group
    Sacramento, California 95841, United States
  • Orange County Retina Medical Group
    Santa Ana, California 92705, United States
  • Southwest Retina Research Center
    Durango, Colorado 81303, United States
  • Colorado Clinical Research
    Lakewood, Colorado 80228, United States
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Fort Lauderdale Eye Institute
    Plantation, Florida 33324, United States
  • Retina Associates of Florida;Retina Associates of Florida
    Tampa, Florida 33609, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina
    Marietta, Georgia 30060, United States
  • Retina Consultants of Hawaii at Pali Momi Medical Center
    ‘Aiea, Hawaii 96701, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Illinois Retina Associates
    Joliet, Illinois 60435, United States
  • University Retina
    Lemont, Illinois 60439, United States
  • Retina Associates
    Lenexa, Kansas 66215, United States
  • Maine Eye Center
    Portland, Maine 04605, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Johns Hopkins Hospital;Johns Hopkins Med;Wilmer Eye Inst
    Baltimore, Maryland 21287, United States
  • Cumberland Valley Retina Consultants;Clinical Research
    Hagerstown, Maryland 21740, United States
  • Associated Retinal Consultants - Royal Oak
    Royal Oak, Michigan 48073, United States
  • VitreoRetinal Surgery PLLC;DBA Retina Consultants of Minnesota
    Minneapolis, Minnesota 55435, United States
  • Pepose Vision Institute
    Chesterfield, Missouri 63017, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Envision Ocular, LLC
    Bloomfield, New Jersey 07003, United States
  • Retina Associates of New Jersey
    Teaneck, New Jersey 07666, United States
  • Retina Vitreous Surgeons of Central New York
    Liverpool, New York 13088, United States
  • New York University (NYU)
    New York, New York 10012, United States
  • Asheville Eye Associates Western Carolina Retinal Associates;Clinical Research
    Asheville, North Carolina 28803, United States
  • Charlotte Eye Ear Nose and Throat Associates- SouthPark;Retina
    Charlotte, North Carolina 28210, United States
  • Duke Eye Center
    Durham, North Carolina 27705, United States
  • Cape Fear Retinal Associates
    Wilmington, North Carolina 28401, United States
  • Ohio State Havener Eye Institute;Ophthalmology Research
    Columbus, Ohio 43212, United States
  • Retina Vitreous Center - Glen Eagles
    Edmond, Oklahoma 73013, United States
  • Retina Northwest;Research Department
    Portland, Oregon 97221, United States
  • Mid Atlantic Retina;Retina Research
    Philadelphia, Pennsylvania 19107, United States
  • Charleston Neuroscience
    Ladson, South Carolina 29456, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Charles Retina Institution;Retina surgery
    Germantown, Tennessee 38138, United States
  • Southeastern Retina Associates
    Knoxville, Tennessee 37922, United States
  • Tennessee Retina
    Nashville, Tennessee 37203, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Retina Associates;Opthalmology
    Austin, Texas 78705, United States
  • Retina & Vitreous of Texas
    Bellaire, Texas 77401, United States
  • Texas Retina Associates;Research
    Dallas, Texas 75231, United States
  • Retina Center of Texas
    Grapevine, Texas 76051, United States
  • Retina Consultants of Texas
    Houston, Texas 77401, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Retina Consultants of Texas
    The Woodlands, Texas 77384, United States
  • Rocky Mountain Retina Consultants
    Murray, Utah 84107, United States
  • Retina Associates of Utah, PLLC;Clinical Research
    Salt Lake City, Utah 84107, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • Wagner Kapoor Institute;Opthalmology
    Norfolk, Virginia 23502, United States
  • Retina Institute of Virginia
    Richmond, Virginia 23235, United States
  • Pacific Northwest Retina
    Silverdale, Washington 98383, United States
  • Spokane Eye Clinical Research;Spokane Eye Surgery Center
    Spokane, Washington 99204, United States
  • Emanuelli Research & Development Center
    Arecibo, 612, Puerto Rico
09

References and documents

Publications

  • Pieramici DJ, Awh CC, Chang M, Emanuelli A, Holekamp NM, Hu AY, Suner IJ, Wykoff CC, Brittain C, Howard D, Quezada-Ruiz C, Santhanakrishnan A, Latkany P. Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial. JAMA Ophthalmol. 2025 Apr 1;143(4):317-325. doi: 10.1001/jamaophthalmol.2025.0001. PubMed 40048178 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2022, 25 months.

Results were first posted in Nov 2025, 3 years 1 month after primary completion. A results delay was requested in Sep 2023.

Of 21 phase 3 interventional studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 41. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2020
First posted
Aug 7, 2020
StartActual
Aug 10, 2020
Primary completionActual
Oct 3, 2022
CompletionActual
Feb 23, 2026
Results delay requested
Sep 7, 2023
Results first posted
Nov 25, 2025
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04503551
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 7, 2020
Start date
Aug 10, 2020
Primary completion
Oct 3, 2022
Completion
Feb 23, 2026
Results posted
Nov 25, 2025
Last update
Apr 2, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion